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Background: Early Right heart failure (RHF) after left ventricular assist device (LVAD) implantation has been well studied. However, the significance 
of late RHF (LRHF) remains unclear. This study aimed to assess the predictors and outcomes of LRHF after LVAD implantation.
methods: A retrospective analysis of 73 consecutive patients implanted with HeartMate II LVAD was conducted. 23 (32%) patients presenting with 
New York Heart Association (NYHA) Class III symptoms, systemic congestion, and severe RHF on echocardiogram 1 month after LVAD implantation 
comprised the LRHF group. 50 (68%) patients had no signs of RHF (NRHF group). The Model for End-Stage Liver Disease (MELD) XI scores was 
calculated for all patients.
results: The LRHF group patients were more often assigned for destination therapy (56% vs. 27%, p=0.01), had higher pre-operative MELD XI score 
(16.2 ± 4.4 vs. 13.8 ±3.2, p=0.03), lower serum albumin level (3.1 ± 0.7 vs. 3.4 ± 0.5 g/dl), tendency to higher central venous pressure (CVP, 15 ± 
5 vs. 13 ± 6 mm Hg, p=0.06) and higher ratio of right ventricle to left ventricle diastolic dimension (RVDD/LVDD: 0.7 ± 0.2 vs. 0.6 ± 0.1, p=0.07) 
on pre-operative echocardiogram compared to the NRHF group. Preoperative MELD XI score ≥ 17 was identified in 54% of the LRHF group patients 
and 10% of the NRHF group patients (p = 0.001) and was the only independent predictor of LRHF (odds ratio 6.8, confidence interval 1.6 - 23.1, p 
= 0.009) by multivariate analysis. At 6 months the LRHF patients had higher serum creatinine (1.4 ± 1.1 mg/dl vs. 1.1 ± 0.2, p=0.03), higher CVP 
(14.5 ± 5.7 vs. 6.3 ± 2.9 mm Hg) and RVDD/LVDD (0.8 ± 0.2 vs. 0.7 ± 0.2, p= 0.05) compared to NRHF group. In addition, 7 (29%) patients of the 
LRHF group versus 5 (10%) patients of the NRHF group died over 9.5 ± 6.3 months follow up period (p=0.04).
conclusions: LRHF may be predicted by pre-operative MELD XI score ≥ 17. LRHF persisted up to 6 months after LVAD implantation, and was 
associated with a higher mortality.
